Skip to main content

Find Clinical Trials

Home
Conditions
Hemic and Lymphatic Diseases

Clinical trial condition

Hemic and Lymphatic Diseases

Explore clinical trials studying Hemic and Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

21,074 public trials 3,988 recruiting studies

Refine in advanced search Browse all conditions

Hemic and Lymphatic Diseases trial results

Suspended

Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease

NCT05028621

Conditions: Castleman Disease, Castleman's Disease (CD), Hemic and Lymphatic Diseases, +12 more
Locations: Cleveland Clinic, Case Comprehensive Cancer Center Cleveland, Ohio, United States

View Trial Details

Suspended

Pembrolizumab in Neoplasms or Lymphomas

NCT03316573

Conditions: Dendritic Cell Sarcoma, Follicular, Dendritic Cell Sarcoma, Interdigitating, Follicular Dendritic Cell Sarcoma, +12 more
Locations: Northwestern University Chicago, Illinois, United States

Massachusetts General Hospital Boston, Massachusetts, United States

Dana Farber Cancer Institute Boston, Massachusetts, United States

University of Nebraska Omaha, Nebraska, United States

View Trial Details

Suspended

Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

NCT02962661

Conditions: Cardiomyopathies, Cardiomyopathy, Cardiovascular Diseases, +9 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Withdrawn

CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors

NCT07297160

Conditions: Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hematologic Diseases, +23 more
Locations: Texas Children's Hospital Houston, Texas, United States

The Methodist Hospital Houston, Texas, United States

View Trial Details

Withdrawn

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

NCT04579523

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Withdrawn

A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

NCT06597734

Conditions: Advanced Myeloproliferative Neoplasms, Bone Marrow Diseases, Chronic Disease, +13 more
Locations: Not specified

View Trial Details

Withdrawn

Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

NCT07566585

Conditions: AML - Acute Myeloid Leukemia, AML With Mutated NPM1, AML, Adult Recurrent, +11 more
Locations: Washington University at St Louis St Louis, Missouri, United States

View Trial Details

Withdrawn

Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML

NCT07338357

Conditions: AML (Acute Myeloid Leukemia), CAR-T, Hematologic Diseases, +6 more
Locations: Not specified

View Trial Details

Withdrawn

Testing the Sickle Cell Caregiver Collaboration for Child Development (SCCCD) Intervention

NCT06562439

Conditions: Anemia, Anemia, Hemolytic, Anemia, Hemolytic, Congenital, +16 more
Locations: Washington University School of Medicine St Louis, Missouri, United States

View Trial Details

Withdrawn

Pacritinib With Aza for Upfront Myelodysplastic Syndrome

NCT07387354

Conditions: Bone Marrow Disease, Bone Marrow Diseases, Hematologic Diseases, +6 more
Locations: Not specified

View Trial Details